Meningococcal meningitis is an acute infectious bacterial disease. It is transmitted by direct contact, including droplet and discharges from nose and throat of infected persons or carriers. Sudden onset occurs in 1 to 7 days after infection with fever, intense headache, nausea, vomiting, stiff neck, petechial rash, pink macules, and even loss of consciousness and sleeping sickness. Occasional fulminating cases exhibit sudden prostration, ecchymoses, collapse and even shock.
Current epidemic areas:
Africa: Benin, Burkina Faso, Burundi, Chad, Cameroon, Central African Republic, Cote d-Ivoire, Djibouti, Ethiopia, Gambia, Ghana, Guinea, Guinea-bissau, Mali, Niger, Nigeria, Senegal Somali, Sudan, Togo Western Asia: Nepal, Saudi Arabia
the menigoccoccal meningitis vaccine
The vaccine currently in use is a Meningococcal Polysaccharides, Immunity after one vaccination lasts for three years.
(MENINGOCOCCAL POLYSACCHARIDE VACCINE A+C)
Persons who should not be vaccinated
Child under two years of age
Persons with high fever or other serious chronic diseases
Fever of short duration and slight swelling at the site of vaccination may occur within 24 hours after vaccination.
Points to remember
Immunity develops seven days after vaccination. Persons traveling abroad should be vaccinated seven days prior to departure.
Any serious side effects after vaccination should be handled by physicians.